Survodutide vs Glutathione
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideAnti-Aging & LongevityImmune Support
Glutathione- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Glutathione is the body's master endogenous antioxidant tripeptide, composed of glutamate, cysteine, and glycine. It neutralizes reactive oxygen species, supports detoxification in the liver, recycles other antioxidants (vitamins C and E), and plays a central role in immune function, DNA repair, and cellular redox balance.
- Half-Life
- ~7 days
- Minutes to hours depending on route; IV half-life approximately 10-30 minutes
- Admin Route
- SubQ
- Oral (liposomal preferred), Sublingual, Intravenous, Nebulized/inhaled, Topical
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 250-1000 mg per day
- Frequency
- Once weekly
- Once or twice daily
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Primary endogenous antioxidant and free radical scavenger
- Supports hepatic detoxification of xenobiotics and heavy metals
- Recycles vitamins C and E to maintain antioxidant network
- Modulates immune function and T-cell activity
- Skin brightening via inhibition of tyrosinase (IV/topical routes)
- Neuroprotective in oxidative stress-related conditions
- Mitochondrial protection and energy metabolism support
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Oral bioavailability is limited (largely hydrolyzed in gut); liposomal or sublingual forms preferred
- IV administration: rare allergic reactions, vein irritation
- High-dose supplementation may cause zinc depletion over time
- Inhaled glutathione may trigger bronchoconstriction in asthmatics
- Stacks With
- —
- —